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Improving screening and treatment options for patients with epithelial ovarian cancer has
been a major challenge in cancer research. Development of novel diagnostic and thera-
peutic approaches, particularly for the most common subtype, high-grade serous ovarian
cancer (HGSC), has been hampered by controversies over the origin of the disease and
a lack of spontaneous HGSC models to resolve this controversy. Over long-term culture
in our laboratory, an ovarian surface epithelial (OSE) cell line spontaneously transformed
OSE (STOSE).The objective of this study was to determine if the STOSE cell line is a good
model of HGSC. STOSE cells grow faster than early passage parental M0505 cells with
a doubling time of 13 and 48 h, respectively. STOSE cells form colonies in soft agar, an
activity for which M0505 cells have negligible capacity. Microarray analysis identified 1755
down-regulated genes and 1203 up-regulated genes in STOSE compared to M0505 cells,
many associated with aberrant Wnt/β-catenin and Nf-κB signaling. Upregulation of Ccnd1
and loss ofCdkn2a in STOSE tumors is consistent with changes identified in human ovarian
cancers by The Cancer Genome Atlas. Intraperitoneal injection of STOSE cells into severe
combined immunodeficient and syngeneic FVB/N mice produced cytokeratin+, WT1+,
inhibin−, and PAX8+ tumors, a histotype resembling human HGSC. Based on evidence
that a SCA1+ stem cell-like population exists in M0505 cells, we examined a subpopulation
of SCA1+ cells that is present in STOSE cells. Compared to SCA1− cells, SCA1+ STOSE
cells have increased colony-forming capacity and form palpable tumors 8 days faster after
intrabursal injection into FVB/N mice. This study has identified the STOSE cells as the first
spontaneous murine model of HGSC and provides evidence for the OSE as a possible
origin of HGSC. Furthermore, this model provides a novel opportunity to study how normal
stem-like OSE cells may transform into tumor-initiating cells.
Keywords: high-grade serous cancer, stem cell, tumor-initiating cell, syngeneic, ovarian cancer, ovarian surface
epithelium, mouse model of ovarian cancer
INTRODUCTION
Ovarian cancer is the most lethal gynecological malignancy with
an estimated incidence of 238,719 cases in 2012, making it the
eighth most common cancer in women worldwide (1). Epithelial
ovarian cancer (EOC) is the most common type, which is further
divided into endometrioid, clear cell, mucinous, low-grade serous,
and high-grade serous (HGSC). HGSC is the most common and
aggressive subtype of EOC, accounting for the majority of new
cases (2). With a 5-year survival rate of only 40%, a greater under-
standing of HGSC is essential to improve patient outcome (1).
The high mortality rate is due, at least in part, to a lack of screen-
ing methods to detect the disease before it metastasizes within the
peritoneal cavity (3). The main reason for this inability to detect
and diagnose early stage ovarian cancer is a lack of understanding
of disease initiation, made even more challenging due to the cur-
rent debate over the origin of HGSC. HGSC was long thought to
arise from the ovarian surface epithelium (OSE) or inclusion cysts
derived from them (2, 4, 5), but recent evidence has identified the
distal fimbrial epithelium of the fallopian tube as the source for at
least a subset of HGSC (2, 6–8).
To establish experimental models for the study of the initiation
of EOC, much effort has been dedicated to the genetic modifi-
cation of cells from an OSE or fimbrial origin, either in tissue
culture or in vivo. Attempts to model HGSC have been particu-
larly challenging and have yielded inconsistent results (5, 9, 10).
Transgenic approaches have generally involved targeting specific
genes known to be associated with human HGSC. This targeted
approach to tumorigenesis may not be fully reflective of human
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disease for a number of reasons. First, it is unclear, in human dis-
ease, whether commonly mutated genes are normally involved in
disease initiation and/or progression. In addition, the expression
of the designed genetic changes using developmentally regulated
promoters may introduce founder effects that are not reflective of
human disease (9). Furthermore, it has been shown that murine
cells require fewer genetic alterations than human cells to undergo
transformation, again making it difficult to draw conclusions on
the origin of cancer in humans from transgenic murine mod-
els (11, 12) For this reason, spontaneous models of EOC would
be helpful to better understand the origins of this disease, but
these models are rare and limited to the spontaneous develop-
ment of ovarian cancer in hens (13, 14). New spontaneous models
of HGSC are clearly needed to provide opportunities to deter-
mine the molecular basis of ovarian and fallopian tube epithelial
transformation.
There is growing evidence to support the contribution of can-
cer stem cells (CSC) to the initiation and recurrence of cancer.
The CSC theory posits that tumors arise from cells with stem-
like characteristics and these cells underlie tumor heterogeneity
and recurrence (15–17). Stem cells are slowly dividing cells with
drug efflux mechanisms that allow them to escape the effects of
chemotherapeutics that commonly target rapidly dividing cells.
Another characteristic of a stem cell is the ability to generate
multi-lineage progeny. Recurrent cases of HGSC maintain the
heterogeneity of the original tumor suggesting that a cell with
multi-lineage potential underlies tumorigenesis, instead of a single
clone with a survival advantage (15). A cell with all the characteris-
tics of CSCs is still elusive in ovarian cancer but cells with some of
these CSC characteristics, identified by their expression of CD44,
CD133, CD117, CD24, and ALDH1 (3), have been reported. These
CSC-like cells are referred to as tumor-initiating cells (TICs) due
to their increased tumorigenic capacity. The role and identification
of TICs in ovarian cancer is a rapidly growing area of study.
We recently reported the first stem cell marker that identifies a
subpopulation of mouse OSE cells with progenitor cell character-
istics. A population of cells expressing stem cell antigen 1 [SCA1;
aka lymphocyte antigen 6 complex, locus A (LY6A)] is regulated
by ovulation-associated factors present in the follicular fluid and
possesses a number of features of stem cells, including slow growth
and capacity for self-renewal (18). After several years of establish-
ing and growing cultures of mouse OSE cells, one cell line that was
grown for a prolonged period appeared to spontaneously trans-
form. The following body of work describes the characterization
of this spontaneously transformed OSE (STOSE) cell line, demon-
strating that it reliably forms syngeneic HGSC tumors. Testing of
the SCA1+ cells in the parental and transformed cell lines enabled
us to compare the characteristics of these stem cell-like popu-
lations, as well as determine the relative malignant potential of
SCA1+ vs. SCA1− STOSE cells.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
Severe combined immunodeficient (SCID) and FVB/N mice were
obtained from The Jackson Laboratory and housed with a 12 h
light:12 h dark photoperiod. The animals had free access to food
and water and experiments were done in accordance with the
Canadian Council on Animal Care’sGuidelines for theCare andUse
of Animals. Protocols were approved by the University of Ottawa
Animal Care Committee.
MOUSE OSE CELL ISOLATION AND CULTURE
The M0505 OSE cell line was isolated and established in 2005
according to the protocol described in Gamwell et al. (18). Upon
long-term passage of the cells in adherent cultures on tissue culture
plates (Becton Dickinson) using MOSE media (18), the M0505
cell line spontaneously transformed and were from that point
on labeled STOSE cells, which were also maintained in MOSE
medium. The M1107 OSE cell line was established and maintained
using the same methods as the M0505 cell line and is used as an
independent control for mouse OSE cells.
PROLIFERATION ASSAY
M0505 and STOSE cell proliferation was assessed from 1 to 3 days
after seeding 2× 104 cells in 24-well tissue culture dishes (Bec-
ton Dickinson) in MOSE medium. The number of viable cells was
determined using the Vi-CELL XR cell viability analyzer (Beckman
Coulter).
CHROMOSOMAL ANALYSIS
G-band karyotyping of 5-metaphase spreads each of M0505
and STOSE cells was carried out by the Cytogenomics and
Genome Resource Facility at SickKids Hospital, Toronto, ON,
Canada. Briefly, cells were harvested and colcemid (10µg/mL)
was added for 30 min and incubated at 37°C. Cells were washed,
trypsinized, and a single-cell suspension was made. Following
washing, a 0.075 M KCl hypotonic solution was added for 15 min
and incubated at 37oC, and banding patterns were visualized.
CELL CYCLE ANALYSIS
The percentages of cells in G1/G0, S-phase, and G2/M phases
as well as the percentage of apoptotic cells were determined for
M0505 and STOSE cell lines using flow cytometry. Cells were
trypsinized (0.05% trypsin/0.53 mM EDTA, Corning Cellgro),
washed in phosphate-buffered saline (PBS), and 1× 106 cells from
three independent isolations of each cell line were resuspended in
300µL of cold PBS. Cells were fixed in 70% ethanol for 2 h,washed,
and resuspended in 250µL of PBS and 5µL of RNAse A (Sigma
Aldrich) for 1 h. The cell suspension was then incubated for 30 min
with 10µL of propidium iodide (Sigma Aldrich) and the cell cycle
was assessed by flow cytometry using a Beckman Coulter Epics XL
and analyzed by ModFit LT software (Verity Software Inc.). Cell
doublets were identified using fluorescence pulse height vs. area
measurements and excluded from cell cycle analysis.
MICROARRAY ANALYSIS
RNA was extracted from M0505 and STOSE cells (n= 3) using
RNeasy Mini Kit (Qiagen) and cDNA was made using the OneStep
RT-PCR kit (Qiagen). Whole genome expression was determined
using Affymetrix GeneChip Mouse Gene 1.0 ST arrays. Genes were
annotated using T4-MEV software (Dana Farber Cancer Insti-
tute, Boston) and linear fold change was determined from robust
multi-array average (RMA) normalized expression values. Inge-
nuity pathway analysis software (Ingenuity Systems, Qiagen) was
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used to determine functionally relevant clusters of differential gene
expression. Microarray data are publicly accessible from the GEO
database at record GSE54633.
QUANTITATIVE RT-PCR
RNA was extracted using the RNeasy Mini Kit (Qiagen) and cDNA
was made using the OneStep RT-PCR Kit (Qiagen). Quantitative-
PCR was then performed on an ABI 7500 FAST qRT-PCR machine
(Applied Biosystems) using the Taqman gene expression assay
(Life Technologies) and SsoFast gene expression assay (Bio-rad).
Probe (2.5 nmol) and primer (5 nmol) sequences are listed in
Table 1. The level of Tbp was used as an endogenous control in
the Taqman assay and Ppia was used as an endogenous control in
the SsoFast assay.
INTRAPERITONEAL (IP) AND INTRABURSAL (IB) INJECTIONS OF STOSE
CELLS
M0505 and STOSE cells were released from adherent cultures
using trypsin (0.05% trypsin/0.53 mM EDTA), washed with PBS,
and resuspended in PBS. 1× 107 M0505 cells in 500µL of PBS
were injected into the peritoneal cavity of FVB/N mice. 1× 107
STOSE cells in 500µL of PBS were injected into the peri-
toneal cavity of both SCID and FVB/N mice using a 25-gauge
needle (Becton Dickinson). Disease progression was monitored
until humane endpoint was reached, which included 15% weight
gain and/or abdominal distension. Necropsies were performed
at endpoint and tumors were fixed in 10% buffered formalin
for 24 h and then paraffin embedded and sectioned at 5µm for
immunohistochemical analysis.
To perform intrabursal injections of STOSE cells, FVB/N mice
were anesthetized using 3% isoflurane gas and 1% oxygen. A
dorsal incision was made and ovaries were externalized. STOSE
cells (4× 104) were resuspended in 2µL of PBS and injected
under the bursal membrane using a 33-gauge needle and dis-
pensing repeater (Hamilton). Tumor initiation was monitored
every 2 days by palpation of the ovaries by someone blinded to
the experimental groups. Disease progression was monitored until
humane endpoint was reached, at which point tumors were fixed,
embedded in paraffin blocks, and 5µm sections were made for
immunohistochemistry.
IMMUNOHISTOCHEMISTRY
Assessment of the histopathology of IP and IB STOSE tumors
was performed by staining sections with hematoxylin and eosin
(H and E) and by immunohistochemical analysis. Following
deparaffinization in xylenes and rehydration in an ethanol gradi-
ent, antigen unmasking (antigen unmasking solution, Dako) was
performed, followed by blocking endogenous peroxidase activ-
ity using 3% hydrogen peroxide in dH2O. Sections were then
rinsed in PBS. Immunostaining for mouse cytokeratin (pan-
CK; pre-diluted, Abcam), mouse WT1 (1:100, Dako), and mouse
inhibin (1:100, Dako) was performed according to the mouse-on-
mouse kit (Vector). Immunostaining for rabbit PAX8 (1:400, Santa
Cruz Biotechnology) was done by incubating sections with the
PAX8 antibody overnight at 4oC, followed by anti-rabbit horse-
radish peroxidase-labeled polymer (Dako) for 30 min at room
temperature. All sections were counterstained using hematoxylin
Table 1 | Quantitative RT-PCR probe and primer sequences.
Gene Assay Probe/primer sequence
Cdkn2a Taqman Probe: 5′-/56-FAM/AGCAGAGCT/ZEN/AAATCCGG
CCTCAG/3lABkFQ/-3′
Primers: forward, 5′-GCTTCAATCTGTTCCTGGCA-3′,
reverse, 5′-CAACAACTTCCTCTCCTGCTAC-3′
Sfrp1 SsoFast Primers: forward, 5′-CAGTTGTGGCTTTTGCATTG-3′,
reverse, 5′-GAGGGAAGGGAGAGGGTTC-3′
Frzb SsoFast Primers: forward, 5′-GGACGGAGCGGATTTTCCTAT-3′,
reverse, 5′-TGACAGGCTTACATTTGCAACG-3′
Sfrp4 SsoFast Primers: forward, 5′-TGGAGAGATCAACTCAGTAGA
AGG-3′, reverse, 5′-GGCTGGCTATCTGCTTCTTG-3′
Ccnd1 Taqman Probe: 5′-/56-FAM/ATCAAGTGT/ZEN/GACCCGGA
CTGCC/3lABkFQ/-3′
Primers: forward, 5′-CGCTAGAAGTGAAGCTAAG
AAGA-3′, reverse, 5′-CTTTGTGTACCGCTGGGAA-3′
Ikbkε SsoFast Primers: forward, 5′-GGGAGAGTCTTTGCCTGATTC-3′,
reverse, 5′-ATCTCCTGGGCTTGGCTATC-3′
S100a4 SsoFast Primers: forward, 5′-GGAGCTGCCTAGCTTCCTG-3′,
reverse, 5′-TCCTGGAAGTCAACTTCATTGTC-3′
Spp1 SsoFast Primers: forward, 5′-GGAGGAAACCAGCCAAGG-3′,
reverse, 5′-TGCCAGAATCAGTCACTTTCAC-3′
Ppia SsoFast Primers: forward, 5′-AGGGTGGTGACTTTACACGC-3′,
reverse, 5′-GATGCCAGGACCTGTATGCT-3′
Tbp Taqman Probe: 5′-/56-FAM/ACTTGACCT/ZEN/AAAGACCATTGC
ACTTCGT/3lABkFQ/-3′
Primers: forward, 5′-CCAGAACTGAAAATCAACG
CAG-3′, reverse, 5′-TGTATCTACCGTGAATCTTGGC-3′
and developed using diaminobenzidine. Following dehydration
in an ethanol gradient, sections were mounted using Permount
(Fisher Scientific). Images were acquired using the ScanScope CS2
(Aperio).
DNA SEQUENCING
Genomic DNA was extracted from STOSE cells using QIAamp
DNA Blood Mini Kit (Qiagen) and PCR amplified using custom
primers designed to cover each of the 11 exons in the mouse p53
gene. Following electrophoresis on a 1% agarose gel, bands per-
taining to each exon were individually excised under UV light.
DNA was extracted from the agarose gel pieces using the QIAquick
Gel Extraction Kit (Qiagen). Extracted DNA was then diluted
to a concentration of 1 ng/µL and mixed with the appropriate
custom primer (2µM) mapping to each exon. Individual exons
were sequenced using the 3730 DNA analyzer (Applied Biosys-
tems). Sequences were aligned using the DNA Dynamo program
(BlueTractorSoftware).
FLOW CYTOMETRY FOR SCA1 EXPRESSION
M0505 and STOSE cells were trypsinized and a single-cell suspen-
sion was made using a 40µm cell strainer. Cells were resuspended
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in a flow buffer (4% fetal calf serum in 1× PBS) and incubated
with anti-SCA1 allophycocyanin fluorophore-conjugated anti-
body (Miltenyi Biotec) for 15 min at 4oC. Following washing and
resuspension in flow buffer, cells were sorted for SCA1 expression
using the MoFlo cell sorter (Beckman Coulter).
COLONY FORMATION IN SOFT AGAR
Cells were released from adherent cultures using trypsin, washed
with PBS, and a single-cell suspension was achieved by passing
cells through a 40-µm cell strainer. A base layer 1:1 mix of 2×
Ham’s F-12:MOSE medium (Sigma Aldrich) and ultrapure LMP
agarose (Life Technologies) was solidified at 4°C for 30 min and
then warmed to 37°C prior to the addition of the top layer. The
top layer consisting of a 1:1:1 mix of 2.5× 104 cells from single-
cell suspension, 2× Ham’s F-12:MOSE medium, and ultrapure
LMP agarose was added. The top layer was solidified at 4°C for
30 min and then incubated at 37°C for 7 days. Colonies were visu-
alized using the EVOS XL imaging system (Life Technologies) and
counted using ImageJ software.
WESTERN BLOT ANALYSIS
Protein was extracted from M0505 and STOSE cells using M-PER
mammalian protein extraction reagent (GE Healthcare). Tumor
tissue from SCA1+ and SCA1− tumors was homogenized and
protein was extracted using M-PER mammalian protein extrac-
tion reagent. Protein extracts were run on a precast Nupage 4–12%
bis–tris gradient gel (Life Technologies) and transferred to a nitro-
cellulose membrane. Following 1 h blocking in 5% non-fat milk,
membranes were incubated with mouse monoclonal PAX8 (1:500,
Santa Cruz Biotechnology) or mouse monoclonal P53 (1:1000,
Cell Signaling) overnight at 4°C. Following washing, the mem-
branes were incubated with rabbit anti-mouse IgG–HRP (1:5000,
Abcam) for 1 h and developed using Select™ western blotting
detection reagent (GE Healthcare). The same protocol was used
for β-actin using mouse monoclonal anti-β-actin (1:40,000, Sigma
Aldrich) and rabbit anti-mouse IgG-HRP (1:15,000, Abcam).
STATISTICAL ANALYSIS
All experiments were performed at least three times. A Stu-
dent’s t -test was used to determine significant differences between
two experimental conditions. Analysis of variance (ANOVA)
with Tukey’s post-test was used to identify significant differ-
ences between more than two experimental groups. Statistical
significance was assumed at p< 0.05.
RESULTS
CHARACTERIZATION OF M0505 AND STOSE CELL LINES
Early passage M0505 cells grow slowly, having a doubling time of
48 h. The growth rate increases as M0505 cells reach>35 passages
and cells begin to lose the epithelial “cobblestone” morphology
that is characteristic of early passage M0505 cells (data not shown),
and has been reported by others studying spontaneous transfor-
mation of epithelial cells (19). Continual passage of late passage
M0505 cells led to the establishment of the STOSE cell line. STOSE
cells have lost the epithelial “cobblestone” morphology and have
transitioned to a more mesenchymal morphology (Figure 1A). To
determine the malignant potential of STOSE cells in vitro, STOSE
cells were assessed for colony forming efficiency in soft agar, a
measure of anchorage independent growth that is characteristic
of transformed cells (20). STOSE cells formed colonies while early
passage M0505 cells did not (Figure 1B). Another characteris-
tic of transformed cells is rapid growth (20). STOSE cells have a
doubling time of 13 h, almost four times faster than their untrans-
formed M0505 counterpart. The growth rate of STOSE cells in
comparison to early passage (passage 18–20) M0505 cells over 72 h
is shown in Figure 1C. Since a greatly increased growth rate might
be explained by aberrant cell cycle regulation, cell cycle analysis
was used to determine if there were differences in the percentage
of M0505 and STOSE cells in each phase of the cell cycle. Cell
cycle analysis of the M0505 cells (monomers) revealed a large G1
peak (59.6± 1.0%), a minor S-phase population (10.1± 0.3%),
and a surprisingly prominent, putative G2/M peak (28.8± 0.8%)
(Figure 1D). Interestingly, the presence of a small percentage
(1.5%) of hyperploid cells was detected in the analysis by the
ModFit program. The presence of a small population of cells
with abnormal DNA content was then confirmed by karyotype
analysis that identified near-tetraploid M0505 cells (Figure 2B).
In addition, the small number of diploid cells in S-phase was con-
sistent with the observed slow proliferation of this cell line. In
contrast, STOSE cells have a significantly increased proportion of
cells in S-phase (45.2± 0.7%) and, a reduced proportion in the
G1 phase (46.7± 0.7%). The small G2/M population and greatly
increased S-phase population suggests that STOSE cell cycle check-
points may be compromised, which could lead to the observed
acceleration in the rate of proliferation.
Due to the role of aneuploidy in transformation and cancer
and the abnormalities found in the cell cycle analysis, chromo-
somal analysis was performed on M0505 and STOSE cells to
determine if aneuploidy is present. G-band karyotyping of five
metaphase spreads revealed aneuploidy in both M0505 and STOSE
cell lines; two representative karyotypes are shown for each cell line
(Figure 2). STOSE cells have a high degree of aneuploidy with the
majority of the population near-triploid (Figure 2C) and a smaller
polyploid population (Figure 2D). All STOSE cells analyzed have
an addition at the terminal end of chromosome 4. All near-triploid
cases have a loss of chromosome 3, 5, and 8, and all polyploid cases
are also hypoploid for chromosomes 3, 5, and 8 (Figures 2C,D).
Surprisingly, chromosomal analysis of early passage (passage 15)
M0505 cells also revealed some degree of aneuploidy with 2/5
near-tetraploid M0505 cells (Figure 2B), while 3/5 M0505 cells
were near-diploid (Figure 2A). This presence of a near-tetraploid
subset of M0505 cells is in agreement with the presence of M0505
cells with increased DNA content seen in the cell cycle analysis
(Figure 1D). All M0505 cells analyzed have terminal deletions in
chromosomes 1 and 4. All near-diploid cases have a loss of one
chromosome 3, 8, and 12, and all near-tetraploid M0505 cells are
hypoploid for chromosomes 3, 8, and 12 (Figures 2A,B).
MICROARRAY ANALYSIS OF STOSE CELLS
To determine the molecular mechanisms by which M0505 cells
transformed into the STOSE cells, whole genome microarray
analysis was performed on M0505 and STOSE cells and linear fold
changes were calculated for STOSE cells relative to M0505 cells.
The top 10 up- and down-regulated genes in STOSE compared
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FIGURE 1 | STOSE cells exhibit classic characteristics of transformed
cells. (A) Bright-field microscopy of M0505 and STOSE cells. Scale
bar=200µm. (B) Colony forming assay in soft agar comparing M0505 and
STOSE cells. Colonies were visualized after 7 days using bright-field
microscopy. Scale bar=200µm. (C) Growth curve of M0505 and STOSE cells
over 3 days. Error bars represent standard error of the mean (SEM). p<0.001,
two-way analysis of variance. (D) Cell cycle analysis of M0505 and STOSE
cells. Cells were incubated with the fluorescent dye propidium iodide and
analyzed by flow cytometry. The average percentage of cells in G1, S, and
G2/M for STOSE cells and M0505 cells is shown (n=6).
to M0505 cells are presented in Table 2. Interestingly, Ddr2, Ereg,
Glipr1, Calcr, and Ankrd1, all up-regulated in STOSE cells, have
been shown to be up-regulated in primary tumors and ovarian
cancer cells (21–24). Igfbp4 has been shown to be down-regulated
in primary tumors (25, 26). The other up-regulated genes in
STOSE cells: Serpinb8, Epb41l4a, Aif1l, and Mgll have no known
links to ovarian cancer. Five of the 10 most down-regulated genes,
Aldh1a2, Enpp2, Lgfbp5, Thbd, and Uchl1, have been previously
implicated in ovarian cancer (25, 27–34). The remaining genes
among these down-regulated candidates have no previous associ-
ation with ovarian cancer: Gpr64, Gpr126, Cybrd1, Star, Ncf2. In
accord with the more rapid proliferation of STOSE cells, two neg-
ative regulators of Cdk4,Cdkn2b and Cdkn2a, are down-regulated
in STOSE cells 13.4- and 5.8-fold, respectively, and both Ccna2
and Ccnd1 are up-regulated (2.02- and 6.2-fold).
The Cancer Genome Atlas (TCGA) ovarian carcinoma array
is a whole genome array database with analysis of 570 human
HGSC tumors. The TCGA array dataset was analyzed by the Can-
cer Genome Research Analysis Network and two of the top gene
changes in the STOSE cell microarray were among those reported
in the pathways most frequently altered in ovarian carcinomas
(35): downregulation of Cdkn2a (−5.8) and overexpression of
Ccnd1 (+6.2). Overexpression of Ccnd1 is strongly correlated
to decreased progression free survival (36) and loss of Cdkn2a
through mutation or hypermethylation has also been shown in
human ovarian carcinomas (35, 37–39). Ingenuity pathway analy-
sis (IPA) was used to identify functionally related clusters of
gene expression differences from the microarray data. IPA analysis
revealed possible aberrant Wnt/β-catenin and Nf-κB signaling in
STOSE cells. The expression of multiple genes associated with Wnt
signaling are significantly altered including Cdkn2a and downreg-
ulation of Wnt signaling inhibitors Sfrp1 and Frzb. Genes differen-
tially expressed in the Nf-κB pathway include Spp1, S100a4, IkBkε,
and Ccnd1. Interestingly, Ccdn1 is associated with both Wnt/β-
catenin and Nf-κB signaling. Validations of Cdkn2a and Ccnd1, as
well as Wnt/β-catenin and Nf-κB-related genes were performed by
quantitative RT-PCR on three microarray-independent samples of
M0505 and STOSE cells (Figure 3).
STOSE CELLS PRODUCE HGSC TUMORS IN BOTH SCID AND
SYNGENEIC FVB/N MICE
Given that STOSE cells exhibit transformed characteristics in vitro,
their in vivo tumorigenicity was assessed using immunocom-
promised SCID mice and the syngeneic strain of mice, FBV/N.
When STOSE cells (1× 107) were injected IP into four SCID
mice, tumors formed in all mice (4/4) with a median endpoint of
47 days. Tumors were collected from most organs within the peri-
toneal cavity and the average total tumor burden was 2.22± 0.21 g
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FIGURE 2 | Chromosomal analysis of M0505 and STOSE cell lines. G-band
karyotyping of five metaphase spreads was performed for both M0505 and
STOSE cell lines and representative karyotypes are presented. (A) Near-
diploid M0505 cell with 37 chromosomes. (B) Near-tetraploid M0505 cell with
75 chromosomes. (A,B)Terminal deletion of chromosomes 1 and 4 as well as
loss of a chromosome 3, 8, and 12 was evident in all M0505 cells analyzed.
(C) Near-triploid STOSE cell with 54 chromosomes. (D) Polyploid STOSE cell
with 143 chromosomes. (C,D) An addition at the terminal end of chromosome
4 as well as a loss of chromosome 3, 5, and 8 were evident in all STOSE cells
analyzed.
per mouse. All SCID mice had ascites with an average volume
of 5.25± 0.63 mL. Following IP injection of STOSE cells into
immunocompetent syngeneic hosts, STOSE cells were tumori-
genic in all FVB/N mice (4/4) with a median endpoint of 48 days.
Necropsy revealed tumors throughout the peritoneal cavity and
an average total tumor burden of 3.06± 0.21 g per mouse, not
different from the tumors in SCID mice. All STOSE-injected
FVB/N mice had ascites with an average volume of 3.08± 0.92 mL,
also not significantly different from SCID mice (n= 4, p= 0.98).
Intraperitoneal injection of 1× 107 M0505 cells into FVB/N mice
did not result in tumor formation in 107 days (0/6 mice).
Spontaneously transformed OSE-derived tumors from both
SCID and FVB/N mice were analyzed by H and E staining for mor-
phological classification (Figure 4A) and immunohistochemistry
for expression of markers commonly found in human ovarian can-
cers (Figure 4B). Tumor morphology was mixed including regions
of mucinous, undifferentiated, and papillary serous structures.
The most common morphologies are presented in Figure 4A. To
confirm an epithelial origin, tumors were stained for epithelial
cytokeratins using a pan-CK antibody. Both SCID and FVB/N
tumors have strong positive pan-CK staining. Wilms tumor-1
(WT1) positivity is a hallmark of HGSC (40), and all STOSE
tumors stained strongly for WT1. Given the WT1 positivity, the
tumors were examined for expression of another marker of HGSC,
PAX8. All STOSE tumors had strong PAX8 expression. To exclude a
granulosa cell origin of STOSE tumors, the expression of the gran-
ulosa cell marker inhibin was determined. No tumors expressed
inhibin. Thus, STOSE-derived tumors have a pan-CK+, WT1+,
inhibin−, PAX8+ profile, indicating that the STOSE tumors
resemble HGSC. Since almost 100% of HGSC cases present with
p53 mutations (9), DNA sequencing was performed on all 11 exons
of the p53 gene in STOSE cells and no mutations were found (data
not shown).
STOSE CELLS RETAINED A POPULATION OF SCA1+ CELLS THAT
EXHIBIT GREATER MALIGNANT POTENTIAL
We have recently identified SCA1 as a marker of a defined stem-
like population in the OSE (18). Flow cytometry confirmed that
the parental M0505 cell line contains an average SCA1+ pop-
ulation of 14.5± 1.4% (n= 6). Interestingly, STOSE cells have
retained a smaller SCA1+ population, on average 5.8± 0.8%
(n= 11, Figure 5A). To determine if SCA1+ and SCA1− cells
exhibit a difference in malignant potential in vitro, M0505 and
STOSE cells were sorted for SCA1 expression and assayed for
colony forming efficiency in soft agar. SCA1+ STOSE cells formed
significantly more colonies than SCA1− STOSE cells (p< 0.05,
Figure 5B).
Since SCA1+ STOSE cells exhibit a more malignant pheno-
type in vitro, SCA1+ STOSE cell malignancy was tested in vivo.
To determine if SCA1 marks cells with enhanced ability to initiate
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Table 2 | Differential gene expression in STOSE cells as compared to early passage M0505 cells.
Gene symbol Gene name Linear fold
change
Publications relating these
genes to ovarian cancer
Serpinb2 Serine (or cysteine) peptidase inhibitor, clade B, member 2 90.7 Unknown
Epb4.1l4a Erythrocyte protein band 4.1-like 4a 64.7 Unknown
Ddr2 Discoidin domain receptor family, member 2 46.4 (22)
Aif1l Allograft inflammatory factor 1-like 37.8 Unknown
Ereg Epiregulin 35.1 (21)
Glipr1 GLI pathogenesis-related 1 (glioma) 34.6 (23)
Igfbp4 Insulin-like growth factor binding protein 4 33.6 (25)
Calcrl Calcitonin receptor-like 33.1 (26)
Ankrd1 Ankyrin repeat domain 1 (cardiac muscle) 30.4 (24)
Mgll Monoglyceride lipase 29.8 Unknown
Ncf2 Neutrophil cytosolic factor 2 −61.7 Unknown
Star Steroidogenic acute regulatory protein −62.7 Unknown
Uchl1 Ubiquitin carboxy-terminal hydrolase L1 −70.5 (28, 32)
Thbd Thrombomodulin −76.2 (27)
Cybrd1 Cytochrome b reductase 1 −83.0 Unknown
Igfbp5 Insulin-like growth factor binding protein 5 −96.1 (25, 32–34)
Gpr126 G protein-coupled receptor 126 −96.6 Unknown
Gpr64 G protein-coupled receptor 64 −101.3 Unknown
Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 −147.3 (30, 31)
Aldh1a2 Aldehyde dehydrogenase family 1, subfamily A2 −170.6 (29)
FIGURE 3 |Validation of genes differentially expressed in STOSE cells
related toWnt/β-catenin and Nf-κB signaling or in common withTCGA
ovarian carcinoma arrays. Quantitative RT-PCR analysis for Cdkn2a, Sfrp1,
Frzb, Sfrp4, Ccnd1, Ikbkε, S100a4, and Spp1 expression is presented for
M0505 and STOSE cells (n=3). Samples used for validation are
independent of those used for microarray analysis. Error bars represent
SEM and *p<0.05, **p<0.01 by Student’s t -test.
tumors, SCA1+ and SCA1− STOSE cells (4× 104) were injected
IB into 29 FVB/N mouse ovaries, 15 with SCA1− cells and 14
with SCA1+ cells. SCA1+ STOSE cells initiated tumorigenesis
faster than SCA1− STOSE cells with the median times to a pal-
pable tumor of 19 (n= 15) and 27 days (n= 14), respectively
(p< 0.01, Figure 6A). There was no difference in total tumor
burden between the two groups when the mice were euthanized
116 days after STOSE cell injection, with mice having a tumor bur-
den of 2.70± 0.53 g (n= 7) for SCA1− tumors vs. 2.72± 0.32 g
(n= 6) for SCA1+ tumors. At that time point, SCA1+ and
SCA1− STOSE tumors also showed a similar degree of tumor
dissemination, metastasizing consistently to the uterus, stomach,
diaphragm, small and large intestines, spleen, and pancreas.
To determine if the increased initiation rate in SCA1+ com-
pared to SCA1− STOSE tumors resulted in different histolog-
ical presentation, immunohistochemistry was performed using
markers of HGSC. Both SCA1+ and SCA1− STOSE tumors are
pan-CK+, WT1+, inhibin−, and PAX8+ (Figure 6B), with no
gross histological differences evident between SCA1+ and SCA1−
tumors. Western blot analysis confirmed strong PAX8 positivity in
both SCA1+ and SCA1− STOSE tumors (Figure 6C), relative to
the positive control, normal uterine tissue, and to the low level
of expression seen in M0505 and STOSE cells cultured in vitro.
An independent non-tumorigenic normal OSE cell line, M1102,
was used as a negative control. Expression of p53 in SCA1+ and
SCA1− STOSE-derived tumors was determined using western
blot analysis. SCA1+ and SCA1− tumors were positive for p53
expression (Figure 6D).
DISCUSSION
There is substantial need for new models of HGSC that have simi-
lar expression profiles, chromosomal aberrations, and histological
features characteristic of human HGSC. These models should also
account for the multiple origins of HGSC in order to effectively
narrow down screening targets based on the tissue of origin. The
body of work presented here describes the production and char-
acterization of a STOSE cell line. STOSE cells have lost character-
istic epithelial “cobblestone” morphology, have a greatly increased
proliferation rate, and form colonies in soft agar. Interestingly,
there is aneuploidy in both M0505 and STOSE cells, suggesting
that aneuploidy may have preceded transformation. Linear fold
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FIGURE 4 | STOSE produce high-grade serous epithelial tumors in
both SCID and syngeneic FVB/N mice.Tumors were fixed in formalin and
set in paraffin blocks; 5µm sections were used for immunohistochemistry
on SCID and FVB/N STOSE cell-derived tumors. (A) Hematoxylin and eosin
staining of STOSE cell-derived tumors. Scale bars= 100µm. (B) Detection
of the epithelial tumor marker, cytokeratin is presented with uterus as a
positive control. Wilms tumor-1 (WT1) is a marker of HGSC and is shown
with a human high-grade serous ovarian carcinoma as a control. Detection
of the granulosa cell and sex-cord stromal tumor marker, inhibin, is shown
with granulosa cells as a positive control. PAX8 expression is shown with a
fallopian tube (oviduct) positive control. Scale bars=50µm.
changes calculated from M0505 and STOSE cell microarray data
revealed that STOSE cells have differentially expressed genes that
are consistent with human HGSC tumor samples and previous
studies on ovarian cancer cell lines. Tumors with an immunohis-
tochemical profile of HGSC formed in all immunocompromised
SCID and syngeneic FVB/N mice following IP STOSE cell injec-
tions, confirming the potential for STOSE cells to be used as
a syngeneic model of HGSC. Finally, STOSE cells that express
SCA1 appear to be more aggressive, with increased colony forming
efficiency in vitro and faster tumor initiation in vivo.
FIGURE 5 | A SCA1+ population is present in STOSE cells.
(A) Percentage of SCA1+ cells in M0505 (n=6) and STOSE (n=11) cells as
assessed by flow cytometry. *p< 0.01, Student’s t -test. (B) Quantification
of colony formation in soft agar by SCA1+ and SCA1−M0505 and STOSE
cells. Colonies were counted using ImageJ software 7 days after seeding
2.5×104 cells in soft agar. The average number of colonies in five fields of
view is presented (n=3). ANOVA was used to determine significance; bars
with different letters are significantly different.
Recent reviews have discussed the pros and cons of current
models of HGSC (5, 9, 10). Current models have focused on the
use of transgenics, xenografts of human cancer cells, and OSE
cells transformed by genetic engineering in attempts to model
HGSC. These models have had some success in modeling HGSC as
well as low-grade serous, endometrioid, and granulosa cell-derived
tumors, although results of these studies are highly variable and
commonly have strain-dependent phenotypes (5). Most transgen-
ics have focused on the use of the anti-Mullerian hormone type
II receptor (Amhr2 or MISIIR) promoter to drive tumor sup-
pressor knockout or oncogene activation, but its expression in
granulosa cells as well as both ovarian epithelium and fimbria
can confound the results and make the origins of such cancers
unclear (5). Human xenografts into immune-compromised mice
have provided much knowledge on the metastasis and chemore-
sistance of human tumors. The lack of an immune system can
limit some uses of these models, which do not accurately repre-
sent the human tumor microenvironment in which the immune
system has a critical role in tumor progression and response to
treatment (9, 10). Genetically engineered OSE cells have provided
much insight into genes that are sufficient to transform OSE cells
(41, 42), but their involvement in HGSC initiation or progression
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FIGURE 6 | SCA1+ STOSE cells initiate HGSC tumorigenesis faster than
SCA1− STOSE cells. Flow cytometric sorting was used to separate SCA1+
and SCA1− STOSE cells. SCA1+ (n=14) and SCA1− (n= 15) STOSE cells
were injected intrabursally into FVB/N mouse ovaries (4×104 cells/ovary).
(A)The first day ovarian tumors were palpable after day of injection (day 0) is
presented and represents the initiation of tumorigenesis. Black lines
represent median values. *p<0.01, Student’s t -test. (B) Hematoxylin and
eosin (H&E) staining and immunohistochemical staining of pan-cytokeratin
(CK), WT1, inhibin, and PAX8, all commonly used markers to subtype ovarian
carcinoma. Scale bars=50µm. (C) PAX8 (48 kDa) expression in cell lines
and STOSE-derived SCA1+ and SCA1− tumors. Lane 1 is uterus from a
wild-type FVB/N mouse as a positive control. Lane 2 is the normal M1102
OSE cell line as a negative control. Lanes 3–4 are passage 14 and 22 M0505
cells and lane 5 is STOSE cells. Lanes 6–7 and 8–9 represent tumors derived
from SCA1− and SCA1+ STOSE cells, respectively. β-actin (42 kDa) was
used as a loading control. (D) P53 (53 kDa) expression in STOSE-derived
SCA1+ and SCA1− tumors. Lane 1 is a T-antigen expressing CAg–TAg
tumor as a positive control. Lane 2 is brain from a wild-type FVB/N as a
negative control. Lane 3–4 represents STOSE-derived SCA1− and SCA1+
tumors, respectively.
is unknown and manipulating such genes may not represent the
natural progression of disease.
The STOSE cells reported here join a number of other spon-
taneously transformed rat (ROSE) (43, 44) and mouse OSE cell
lines that have been previously reported. Syngeneic mouse mod-
els include ID8, IF5, IG10, L-MOSE, and MOSEC cells (45–48).
These models are all tumorigenic in immunocompetent mice and
allow the study of immunologic parameters as well as serve as a
resource to test immunotherapies in ovarian cancer (48). Sponta-
neous models are beneficial since they arise from specific cell types,
so their origins are clear (49). All of the models derived from
spontaneously transformed OSE cell lines have yielded poorly
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differentiated epithelial carcinomas, but have not been examined
further to confirm their histologic identity as it compares with
human tumors. Those lines tested have shown gene expression
profiles similar to human (3, 50).
The STOSE model is the first spontaneous HGSC model, as
confirmed by the expression of immunohistochemical markers
(pan-CK+, WT1+, inhibin−, PAX8+), consistent with human
ovarian carcinomas (2, 40). The expression of WT1 and PAX8,
commonly used to diagnose HGSC, help to confirm that OSE cells
have the ability to spontaneously transform into HGSC. PAX8
positivity in human HGSC is one of the characteristics used to
support a fimbrial origin of HGSC (2). It is well-established as a
marker of fimbrial epithelium and, due to its expression in HGSC,
much research has now focused on the fimbrial epithelium (2,
4). Recently, a report has shown that PAX8+ tumors can be pro-
duced from transformed hilum cells that originate in the ovary,
providing additional evidence that the OSE cells can be an origin
of HGSC (4). Although OSE cells have little to no PAX8 expres-
sion, our results show that both the untransformed M0505 cells
as well as the STOSE cells had a low level of expression of PAX8+
(Figure 6C), suggesting that early acquisition of PAX8 expression
in the M0505 cells may have facilitated the transformation of these
cells. Further study of PAX8 and its function in M0505 and STOSE
cells will help delineate its role in the transformation process.
The STOSE model is also the first syngeneic ovarian cancer
model in the FVB/N strain of mice. All previous spontaneously
transformed mouse OSE cells have been derived from C57Bl/6
mice (32, 45, 46, 48). Most spontaneous models have been pro-
duced by IP injection into syngeneic hosts, abrogating the ability
to study metastasis from a specific site. The ovarian bursa is a
controlled and distinct microenvironment and we have previ-
ously shown that, while tumor histology is not different when
cells are injected into this location, it is an effective means to iden-
tify more invasive cells, as only aggressive cells can invade the
ovary and/or breach the bursal membrane (51). Injecting cells
under the bursal membrane also provides the ability to study the
immune parameters associated with metastasis that could enable
the production of immune therapies to prevent metastasis. The
spontaneous ID8 model has produced peritoneal metastases fol-
lowing IB injection into their syngeneic C57Bl/6 strain of origin
(52). The STOSE model also forms extensive peritoneal metas-
tases following IB injection, making STOSE the first metastatic
HGSC model in the FVB/N strain. Having spontaneous models in
multiple strains is an important resource to enable investigators
to show that the efficacy of a therapeutic strategy is indepen-
dent of strain background, greatly improving the translation of
therapeutic strategies.
Spontaneously transformed OSE cells are aneuploid and have
gene expression changes consistent with human ovarian cancer.
Aneuploidy is common in many cancers including ovarian can-
cers (19, 39, 45, 46, 53). Aneuploidy is a prognostic determinant
in HGSC since severe aneuploidy is associated with poor outcome
(53). STOSE cells have a high degree of aneuploidy, character-
ized by triploid and polyploid cells. Furthermore, the loss of
genomic stability in both M0505 and STOSE cells as seen by ane-
uploidy may have been an early event leading to transformation
that may explain the tumorigenic capacity of STOSE cells. Loss of
chromosome 3, which contains many tumor suppressors, is seen
in both M0505 and STOSE cells. Haploinsufficiency of chromo-
some 3 tumor suppressors such as Lrrc3b (fold change of−2.69 in
STOSE cells) may underlie transformation (54). Similarly, chro-
mosome 8 is lost in M0505 and STOSE cells and it has been shown
to contain ovarian cancer susceptibility loci, allelic loss of which
may have contributed to transformation (55, 56). Three down-
regulated genes in STOSE cells, Enpp2, Sfrp1, and Star are all
located on chromosome 8. Loss of chromosome 8 in M0505 cells
may have been an early event in transformation (30, 57).
Ingenuity pathway analysis of microarray data revealed gene
expression changes related to Wnt/β-catenin signaling in STOSE
cells suggesting signaling in the Wnt pathway might be aberrant.
Many of the down-regulated genes in STOSE cells are associ-
ated with Wnt/β-catenin signaling and have been associated with
loss of heterozygosity or promoter methylation in ovarian cancer,
including Fzd4, Sfrp1, and Axin2 (58–61). Interestingly, Cdkn2a
is down-regulated in 30% of HGSC cases and Ccnd1 is amplified
in 4% of the cases, according to TCGA ovarian carcinoma array
(35). STOSE cells have a similar expression pattern of Cdkn2a and
Ccnd1.Cdkn2a andCcnd1 are both associated with Wnt/β-catenin
signaling. Ccnd1 is a well-established target gene of β-catenin sig-
naling and has a role in promoting cell cycle progression, while
Cdkn2a encodes a cell cycle inhibitor that is suppressed by β-
catenin (35, 62, 63). Due to the association of these two genes
with human HGSC and aberrant Wnt signaling in STOSE cells,
further study of the role of Cdkn2a, Ccnd1, and Wnt/β-catenin
signaling is needed to understand the role Wnt/β-catenin signal-
ing in the transformation of M0505 cells into STOSE cells or in the
tumorigenic capacity of STOSE cells. A greater understanding of
this pathway may translate to greater knowledge on the initiation
and progression of HGSC.
Interestingly, Aldh1a2 is the most down-regulated gene in
STOSE cells (−170.58 fold). Aldh1a2 is involved in retinoic acid
(RA) biosynthesis and has been shown to have ubiquitous expres-
sion in the human ovarian surface epithelium (2, 29). The RA-
receptor β (Rarβ) is also down-regulated in STOSE cells (−10.80
fold) suggesting multiple aspects of RA signaling are lost. RA sig-
naling has been shown to crosstalk with Wnt/β-catenin signaling
and Aldh1a2 has also been identified as a tumor suppressor in
prostate cancer, loss of which is an early event in the disease (64,
65). Further study of Alhd1a2, RA signaling, and the crosstalk
between RA and Wnt/B-catenin signaling may help determine
the mechanisms leading to transformation and tumorigenesis
in HGSC.
Investigation of a potential TIC population in the STOSE
revealed that STOSE cells have retained a SCA1+ population that
appears to have a more malignant phenotype than SCA1− STOSE
cells. TICs have been thought to be key contributors to HGSC
etiology based on the heterogeneity and recurrence that are char-
acteristic of the disease (3, 15, 50). TICs have been identified in
both human and murine ovarian cancers by sorting for CD44,
CD133, CD117, CD24, ALDH1, and SCA1 expression alone or in
combination (3, 15). SCA1 has also been used for the enrichment
of a stem cell population in leukemia, prostate, and breast cancers
(15). STOSE cells were found to contain a SCA1+ population that
exhibits increased malignancy both in vitro as assessed by colony
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formation and in vivo as assessed by initiation of tumorigenesis.
Interestingly, SCA1+ and SCA1− STOSE-derived tumors were
positive for p53 expression by western blot analysis. DNA sequenc-
ing showed no mutations in the p53 gene, suggesting pathways that
lead to p53 stabilization might also be aberrant in STOSE cells. Our
findings that the SCA1+ population exhibits TIC characteristics is
in line with a recent study on SCA1+ cells in the T2 mouse model
of ovarian cancer, which showed that these cells have TIC char-
acteristics that allow them to escape chemotherapy and produce
heterogeneous tumors following treatment (15). The retention of
a SCA1+population with TIC characteristics allows us to compare
tumorigenic SCA1+ STOSE cells with non-tumorigenic SCA1+
M0505 cells.
In summary, this study has led to the development of a spon-
taneously transformed syngeneic model of HGSC in the FVB/N
mouse, the first spontaneous murine model with defined features
of HGSC. The STOSE model has characteristics of human disease
such as aneuploidy, gene expression, and the presence of a TIC
population. This model also produces extensive metastases in the
peritoneal cavity following IB injection allowing for the study of
tumor dissemination. Further investigation is required to under-
stand the contribution of Wnt/β-catenin signaling in STOSE cells.
The STOSE model offers vast potential for testing of novel ther-
apeutics, including immune therapies. This model will also allow
for the discovery of new screening targets that are involved in the
transition of normal cells to HGSC.
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